A retrospective study on the efficacy of a ten-milligram dosage of @entity2993 for treatment of @entity1007 in @entity6 XXXX .

@entity1 @entity1007 @entity6 @entity2993 @entity11429 @entity165
BACKGROUND: There have been few clinical studies on 10 mg @entity2993 as a starting dosage for treatment of @entity1007 in @entity6 ( @entity6 ) @entity1 . This retrospective study aims to evaluate the efficacy of 10 mg dosage of @entity2993 in clinical setting. METHODS: One hundred five enrolled @entity1 with high levels of low density lipoprotein @entity165 ( @entity11429 , > 100 mg/dL) took 10 mg @entity2993 . After 6 months, they were divided into 'Responder group' ( @entity11429 < 100 mg/dL) and 'Non-responder group' ( @entity11429 >=  100 mg/dL), and the response rate was calculated. Thereafter, we subdivided the 'Responder group' into Maintenance (10 mg), Reduced dosage (5 mg), and Discontinuance group (0 mg). The 'Non-Responder group' was subdivided into Maintenance (10 mg) and Double dosage group (20 mg). After consecutive 6 months, the response rates of each 10 mg Maintenance groups were compared to those of the other groups, respectively. RESULTS: Following the first 6 months, the response rate of 10 mg fixed dosage was 74.3%. In the 'Responder group', response rates of 10 mg, 5 mg and Discontinuance groups following 6 months were 52.6%, 53.1%, and 12.5%, respectively. In the 'Non-responder group', response rates of 10 mg and 20 mg groups were 28.6% and 50.0%. Baseline @entity11429 levels and body mass index (BMI) of 'Responder group' were significantly lower than those of 'Non-responder group' (P = 0.004, respectively). CONCLUSION: @entity1007 treatment with 10 mg, fixed dosage of @entity2993 was effective in three quarters of the subjects during the first 6-month treatment; however, a significant number of @entity1 with high @entity11429 levels and/or BMI require higher starting and maintenance dosage.
